United Therapeutics Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Martine A. Rothblatt
- Full Time Employees
- 1,400
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1040 Spring Street Silver Spring MD United States of America 20910
- IPO Date
- Jun 17, 1999
- CIK
- 0001082554
- Website
- unither.com
- Similar Companies
- Business
- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit biotechnology company founded in 1996 and headquartered in Silver Spring, Maryland, with co-headquarters in Research Triangle Park, North Carolina, develops and commercializes innovative products to address unmet medical needs of patients with chronic and life-threatening diseases, particularly pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), high-risk neuroblastoma, and organ failure; its core commercial portfolio includes Tyvaso DPI and Tyvaso, inhaled formulations of treprostinil via dry powder inhaler and nebulizer for PAH and other lung conditions; Remodulin (treprostinil) injection and Orenitram (treprostinil extended-release tablets) for PAH to improve exercise capacity and delay disease progression; Adcirca (tadalafil), an oral PDE-5 inhibitor for PAH; Unituxin (dinutuximab) injection, a monoclonal antibody for pediatric high-risk neuroblastoma; and Remunity Pump, a subcutaneous delivery system for Remodulin. The company operates in the United States, Canada, Central and South America, Europe, the Middle East, and Asia through distribution partners and maintains manufacturing facilities in locations including Melbourne and Jacksonville, Florida; Blacksburg, Virginia; Manchester, New Hampshire; and Magog and Bromont, Quebec. United Therapeutics targets patients with cardiovascular, pulmonary, oncology, and organ transplant needs, while advancing a pipeline featuring RemoPro and ralinepag for PAH, Aurora-GT gene therapy for lung vascular rebuilding, nebulized Tyvaso for IPF, and xenotransplantation technologies including UKidney for end-stage renal disease via xenografts, allogenic recellularization, and bioprinting. In recent developments, United Therapeutics announced the first human transplant in its EXPAND clinical trial of UKidney for end-stage renal disease in November 2025, marking a milestone in xenotransplantation; the company reported positive top-line results from the phase 3 TETON-2 pivotal study of nebulized Tyvaso in IPF in September 2025, meeting the primary endpoint and key secondary measures across subgroups; it initiated a $1 billion accelerated share repurchase program in August 2025 with Citibank to return capital to shareholders while supporting growth; and earlier acquired IVEVA and MiroMatrix to bolster organ manufacturing expertise, alongside investments in new manufacturing facilities and designated pathogen-free sites.
Company News
United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock
Biotech Options Buzz: UTHR, NMRA, EWTX
Corient Private Wealth LP Reduces Stake in United Therapeutics Corporation $UTHR
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
Analyzing United Therapeutics (NASDAQ:UTHR) and Zenas BioPharma (NASDAQ:ZBIO)
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
Hsbc Holdings PLC Raises Stake in United Therapeutics Corporation $UTHR
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR
Freestone Grove Partners LP Acquires New Stake in United Therapeutics Corporation $UTHR
Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH